Correspondence 0001683168-24-003530 from CNS Pharmaceuticals, Inc. (CNSP)
CNS Pharmaceuticals, Inc.
Date: May 15, 2024 · CIK: 0001729427 · Accession: 0001683168-24-003530
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-279285
Letter
CNS Pharmaceuticals, Inc.
2100 West Loop South, Suite 900
Houston, TX 77027
May 15, 2024
VIA EDGAR
U.S. Securities and Exchange Commission
Division of Corporate Finance
Washington, DC 20549
Attention: Lauren Hamill
Re: CNS Pharmaceuticals, Inc.
Registration Statement on Form S-3
Registration No. 333-279285
Ladies and Gentlemen:
Pursuant to Rule 461 of the Securities Act of 1933, as amended, CNS Pharmaceuticals, Inc., a Nevada corporation (the “Company”), hereby respectfully requests that the effective date for the Registration Statement referred to above be accelerated so that it will be declared effective at 4:00 P.M. (Eastern Time) on May 17, 2024, or as soon thereafter as possible on such date.
Very truly yours,
CNS Pharmaceuticals, Inc.
Show Raw Text
CORRESP 1 filename1.htm CNS Pharmaceuticals, Inc. 2100 West Loop South, Suite 900 Houston, TX 77027 May 15, 2024 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporate Finance Washington, DC 20549 Attention: Lauren Hamill Re: CNS Pharmaceuticals, Inc. Registration Statement on Form S-3 Registration No. 333-279285 Ladies and Gentlemen: Pursuant to Rule 461 of the Securities Act of 1933, as amended, CNS Pharmaceuticals, Inc., a Nevada corporation (the “Company”), hereby respectfully requests that the effective date for the Registration Statement referred to above be accelerated so that it will be declared effective at 4:00 P.M. (Eastern Time) on May 17, 2024, or as soon thereafter as possible on such date. Very truly yours, CNS Pharmaceuticals, Inc. By: /s/ Christopher Downs Name: Christopher Downs Title: Chief Financial Officer